small molecule

RYANODEX

DANTROLENE SODIUM

Loss of exclusivityloss of exclusivity
CompanyEAGLE PHARMACEUTICALS INC

Drug detail

Brand nameRYANODEX
Active ingredientDANTROLENE SODIUM
Strength250MG/VIAL
Dosage formFOR SUSPENSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2014
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RYANODEX patent cliff — loss of exclusivity — | CliffBio